In the latest quarter Q4'25, Eli Lilly's (LLY) Gross Margin stood at 82.5%, Operating Margin reached 45.8%, and Net Profit Margin was 34.4%, reflecting robust profitability with all metrics showing year-over-year improvements from Q4'24 levels of 82.2%, 37.2%, and 32.6%, respectively. Over the period from Q1'23 to Q4'25, the chart reveals an overall upward trend in profit margins, with Gross Margin steadily increasing from 76.6% to 82.5% and exhibiting minimal volatility, indicating strong cost management in core operations. Operating and Net Profit Margins displayed more fluctuation, including dips to 4.5% and -0.6% in Q3'23 due to potential one-time expenses, but both recovered strongly, peaking at 45.8% and 36.4% in Q2'25 before stabilizing at elevated levels, underscoring improved operational efficiency and net earnings growth amid the company's pharmaceutical expansions.